G1 Therapeutics (GTHX) Investor Presentation - Slideshow

COSELA (Trilaciclib) Overview - COSELA is the first and only therapy to help protect against chemotherapy-induced myelosuppression for ES-SCLC patients receiving certain chemotherapy treatments [7] - COSELA demonstrated meaningful benefits across studies, including reduced rates of hematologic adverse events and improved immune response [16] - COSELA is approved by the U S Food and Drug Administration to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with ES-SCLC [23] Financial Status and Objectives - The company had $207 million in cash on hand as of December 31, 2020, with an additional $86 4 million in net proceeds from Cowen ATM during 1Q21 [7] - A key objective is to establish COSELA as the Standard of Care for ES-SCLC patients in the U S [21, 22, 35, 36, 42, 53, 56] - The company aims to maximize the long-term value of COSELA by executing a robust development plan [21, 22, 35, 36, 42, 53, 56] Clinical Trial Results and Expansion Opportunities - In a study, patients treated with COSELA prior to Etoposide, Carboplatin, and Atezolizumab experienced a Duration of Severe Neutropenia (DSN) of 0 days compared to 4 days in the placebo group (p<0 0001) [24] - In the same study, only 1 (1 9%) of patients in the COSELA group experienced severe neutropenia compared to 26 (49 1%) in the placebo group (p<0 0001) [24] - Pooled data from three randomized placebo-controlled trials showed a 53% reduction in severe neutropenia with COSELA compared to placebo [37] - The company is aggressively pursuing development in areas of high strategic importance where COSELA is most likely to provide meaningful benefits to patients [18] Market and Launch - Approximately 30,000 ES-SCLC patients are treated annually in the U S [32] - The U S launch of COSELA in ES-SCLC occurred in 1Q 2021 [17, 18, 21, 22, 35, 36, 42, 53, 56, 62] - Internal market research indicates 77% of prescribers are either extremely or very enthusiastic to use COSELA for patients with ES-SCLC following education [34]